Vaccine optimization for COVID-19, who to vaccinate first?
Open Access
- 16 August 2020
- preprint content
- other
- Published by Cold Spring Harbor Laboratory in medRxiv
Abstract
A vaccine, when available, will likely become our best tool to control the current COVID-19 pandemic. Even in the most optimistic scenarios, vaccine shortages will likely occur. Using an age-stratified mathematical model, we determined optimal vaccine allocation for four different metrics (deaths, symptomatic infections, and maximum non-ICU and ICU hospitalizations) under a wide variety of assumptions. We find that a vaccine with effectiveness ≥50% would be enough to substantially mitigate the ongoing pandemic provided that a high percentage of the population is optimally vaccinated. When minimizing deaths, we find that for low vaccine effectiveness, it is optimal to allocate vaccine to high-risk (older) age-groups first. In contrast, for higher vaccine effectiveness, there is a switch to allocate vaccine to high-transmission (younger) age-groups first for high vaccination coverage. While there are other societal and ethical considerations, this work can provide an evidence-based rationale for vaccine prioritization.This publication has 21 references indexed in Scilit:
- COVID-19 vaccines for all?The Lancet, 2020
- COVID-19 vaccine development pipeline gears upThe Lancet, 2020
- COVID-19 and Racial/Ethnic DisparitiesJAMA, 2020
- Serial interval of novel coronavirus (COVID-19) infectionsInternational Journal of Infectious Diseases, 2020
- Projecting social contact matrices in 152 countries using contact surveys and demographic dataPLoS Computational Biology, 2017
- Derivative-Free and Blackbox OptimizationPublished by Springer Science and Business Media LLC ,2017
- Optimizing Vaccine Allocation at Different Points in Time during an EpidemicPLOS ONE, 2010
- Implementing the Nelder-Mead simplex algorithm with adaptive parametersComputational Optimization and Applications, 2010
- Optimizing Influenza Vaccine DistributionScience, 2009
- Interpretation and Estimation of Vaccine Efficacy under HeterogeneityAmerican Journal of Epidemiology, 1992